Zacks Research Analysts Lower Earnings Estimates for Zoetis

Zoetis Inc. (NYSE:ZTS) – Zacks Research lowered their FY2026 earnings per share estimates for Zoetis in a research note issued on Thursday, March 6th. Zacks Research analyst E. Bagri now expects that the company will post earnings per share of $6.55 for the year, down from their prior estimate of $6.97. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q4 2026 earnings at $1.66 EPS.

ZTS has been the subject of several other reports. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Stock Down 4.3 %

ZTS stock opened at $164.39 on Monday. The firm has a market cap of $73.61 billion, a price-to-earnings ratio of 30.05, a PEG ratio of 2.78 and a beta of 0.94. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.33. The firm has a fifty day moving average price of $166.94 and a two-hundred day moving average price of $176.55. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Transactions at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last three months. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Menard Financial Group LLC grew its stake in Zoetis by 11.4% during the 4th quarter. Menard Financial Group LLC now owns 1,957 shares of the company’s stock valued at $319,000 after acquiring an additional 201 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $87,984,000. Azzad Asset Management Inc. ADV grew its position in Zoetis by 1.7% during the fourth quarter. Azzad Asset Management Inc. ADV now owns 11,741 shares of the company’s stock valued at $1,913,000 after purchasing an additional 196 shares in the last quarter. Capital A Wealth Management LLC acquired a new position in Zoetis in the 4th quarter valued at approximately $259,000. Finally, Cypress Asset Management Inc. TX purchased a new stake in Zoetis in the 4th quarter worth approximately $4,593,000. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.